[MO31] Mini-Oral Session 31　臨床試験推進プログラム1（Trial in Progress）

[MO31-2] 治療歴を有するc-Met陽性進行性非小細胞肺癌患者を対象としたTelisotuzumab vedotin単剤療法

^○堀之内 秀仁¹, Goldman J.W.², MoiseenKo F.³, Cicin I.⁴, Filippova E.⁵, Bar J.⁶, Tomasini P.⁷, Ocampo C.⁸, Sullivan D.⁸, Maag D.⁸, Motwani M.⁸, Jin J.⁸, Camidge D.R.⁹ (1.国立がん研究センター中央病院, 2.David Geffen School of Medicine at UCLA, Los Angeles, CA/United States of America, 3.St. Petersburg City Cancer Center, St. Petersburg/Russian Federation, 4.Trakya University Medical Center, Edirne/Turkey, 5.Center of Palliative Medicine De Vita, St. Petersburg/Russian Federation, 6.Sheba Medical Center, Ramat Gan/lsrael, 7.Aix Marseille Univ, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille/France, 8.AbbVie, Inc., North Chicago, IL/United States of America, 9.University of Colorado Cancer Center, Aurora, CO/United States of America)